<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01026116</url>
  </required_header>
  <id_info>
    <org_study_id>SHBCC09007</org_study_id>
    <nct_id>NCT01026116</nct_id>
  </id_info>
  <brief_title>A Randomized Trial Comparing Epirubicin/Cyclophosphamide Followed by Weekly Paclitaxel Versus Epirubicin/Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old</brief_title>
  <acronym>PAY</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Manifold data revealed that young breast cancer patients are characterized by aggressive
      clinical history. The purpose of this study is to evaluate the efficacy and safety of
      different strategies incorporating paclitaxel to anthracycline-based regimens in young breast
      cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2009</start_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>every one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>every one year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">1664</enrollment>
  <condition>Breast Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A</intervention_name>
    <description>epirubicin/cyclophosphamide followed weekly paclitaxel</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B</intervention_name>
    <description>epirubicin/paclitaxel followed by weekly paclitaxel</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients, age 18~40

          -  Unilateral, operable, histologically confirmed adenocarcinoma of the breast

          -  Stage I-III

          -  Primary surgery with clear margins plus axillary dissection

          -  Able to start protocol Rx within 4 weeks of surgery

          -  HER-2 positive (IHC 3+ OR FISH+) and sequential use of trastuzumab followed by
             chemotherapy

          -  Occult breast cancer with histologically confirmed primary invasive carcinoma or DICS
             with microinvasion in the ipsilateral breast after surgery

          -  ECOG performance status 0-1

          -  Adequate cardiac, renal, hepatic and hematologic function

        Exclusion Criteria:

          -  Metastatic disease

          -  Bilateral breast cancer (synchronous or metachronous)

          -  Prior radiation therapy, hormonal therapy and chemotherapy for breast cancer

          -  Previous cancer (except treated basal cell and squamous cell carcinoma of the skin or
             cancer of the uterine cervix)

          -  HER-2 positive (IHC 3+ OR FISH+) and concurrence use of adjuvant chemotherapy and
             trastuzumab

          -  Documented history of cardiac disease contradiction anthracyclines

          -  Concurrent serious illness

          -  Peripheral neuropathy of CTC grade&gt;1

          -  History of hypersensitivity to drugs formulated in Cremophor EL polyoxyethylated
             castor oil), the vehicle used for commercial paclitaxel formulations

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhimin Shao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital, Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenjin Yin</last_name>
    <phone>86(21)64175590</phone>
    <phone_ext>8700</phone_ext>
    <email>followroad@yahoo.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Breast Surgery, Cancer Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wenjin Yin</last_name>
      <phone>86(21)64175590</phone>
      <phone_ext>8700</phone_ext>
      <email>followroad@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Zhimin Shao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Breast Surgery, Cancer Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhimin Shao</last_name>
      <phone>86(21)64175590</phone>
      <phone_ext>8807</phone_ext>
      <email>zhimingshao1962@yahoo.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Wenjin Yin</last_name>
      <phone>86(21)64175590</phone>
      <phone_ext>8700</phone_ext>
      <email>followroad@yahoo.com.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Zhimin Shao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2009</study_first_submitted>
  <study_first_submitted_qc>December 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2009</study_first_posted>
  <last_update_submitted>December 3, 2009</last_update_submitted>
  <last_update_submitted_qc>December 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Base for drug clinical trials, Cancer Hospital, Fudan University</name_title>
    <organization>Department of Breast Surgery, Cancer Hospital, Fudan University</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

